Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Therapeutic resistance in castration-resistant prostate cancer: co-targeting strategies against

Christopher P. Evans

4 Therapeutic resistance in castration-resistant prostate cancer: co-targeting strategies against; Christopher P. Evans

Primary resistance to chemotherapeutics available for the treatment of castration resistant prostate cancer isn’t uncommon. Professor Christopher Evans, UC Davis School of Medicine Sacramento, California, focusses on key mechanisms in androgen synthesis, androgen splicing, docetaxel and metabolic resistance that give rise to drug resistance. Treatment induced stress response is the upregulation of androgen synthesis enzymes, the expression of androgen receptor variants like AR-V7, increased drug efflux mediated by ABCB1 or enhanced autophagy. Professor Evans presents co-targeting strategies to recover drug sensitivity.